Literature DB >> 26785642

Clinical features and natural course of acromegaly in patients with discordance in the nadir GH level on the oral glucose test and the IGF-1 value at 3 months after adenomectomy.

Yasuyuki Kinoshita1, Atsushi Tominaga2, Satoshi Usui2, Kazunori Arita3, Tetsuhiko Sakoguchi4, Kazuhiko Sugiyama5, Kaoru Kurisu2.   

Abstract

Discordant GH and IGF-1 levels after adenomectomy are well recognized in acromegalics. The aim of this study was to evaluate the clinical features and natural course of postoperative acromegaly associated with discordant GH and IGF-1 levels over a postoperative period. A total of 69 acromegalics underwent surgery with at least 1 year of follow-up and received 75-g oral glucose tolerance tests (OGTTs) at 3 months postoperatively. The patients were categorized into four groups according to the postoperative nadir GH levels and IGF-1 levels: controlled group (normal GH and normal IGF-1), high-IGF-1 group (normal GH and high IGF-1), high-GH group (high GH and normal IGF-1), and uncontrolled group (high GH and high IGF-1). The incidence of discordant GH and IGF-1 levels was 27.5%: high-IGF-1 group = 10.1% (n = 7) and high-GH group = 17.4% (n = 12). All patients in the high-IGF-1 group exhibited a decline in the IGF-1 level after surgery, with normalization observed in 71.4% of the patients without additional treatment (median 23 months). These subjects had preoperatively high IGF-1 levels despite not demonstrating higher GH levels than the patients in the controlled group. On the other hand, four patients in the high-GH group exhibited an elevated nadir GH level higher than 1.0 μg/L on repeated OGTTs after 3 months, and one patient experienced a recurrence of acromegaly. Patients in the high-IGF-1 group require no additional treatments, and their IGF-1 levels are likely to normalize within a few years. However, patients in the high-GH group should be carefully followed due to the possibility of recurrence.

Entities:  

Keywords:  Acromegaly; Discordance; Growth hormone; Insulin-like growth factor-1; Natural history

Mesh:

Substances:

Year:  2016        PMID: 26785642     DOI: 10.1007/s10143-015-0692-5

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  25 in total

1.  Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development.

Authors:  Daniela Milani; John D Carmichael; Joan Welkowitz; Steven Ferris; Richard E Reitz; Ann Danoff; David L Kleinberg
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

Review 2.  The critical parameters in GH excess.

Authors:  M C Sheppard
Journal:  J Endocrinol Invest       Date:  2005       Impact factor: 4.256

3.  Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.

Authors:  Annamaria Colao; Rosario Pivonello; Luigi M Cavallo; Maria Gaccione; Renata S Auriemma; Felice Esposito; Paolo Cappabianca; Gaetano Lombardi
Journal:  Clin Endocrinol (Oxf)       Date:  2006-08       Impact factor: 3.478

Review 4.  Modulation of growth hormone action by sex steroids.

Authors:  Udo J Meinhardt; Ken K Y Ho
Journal:  Clin Endocrinol (Oxf)       Date:  2006-10       Impact factor: 3.478

5.  Basal, but not pulsatile, growth hormone secretion determines the ambient circulating levels of insulin-like growth factor-I.

Authors:  Alexander T Faje; Ariel L Barkan
Journal:  J Clin Endocrinol Metab       Date:  2010-02-26       Impact factor: 5.958

6.  Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method.

Authors:  Tsuyoshi Isojima; Akira Shimatsu; Susumu Yokoya; Kazuo Chihara; Toshiaki Tanaka; Naomi Hizuka; Akira Teramoto; Ke-ita Tatsumi; Katsuhiko Tachibana; Noriyuki Katsumata; Reiko Horikawa
Journal:  Endocr J       Date:  2012-05-19       Impact factor: 2.349

7.  Use of the oral glucose tolerance test to define remission in acromegaly.

Authors:  H Vierhapper; G Heinze; A Gessl; M Exner; C Bieglmayr
Journal:  Metabolism       Date:  2003-02       Impact factor: 8.694

8.  Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR.

Authors:  Evelyn Oliveira Machado; Giselle F Taboada; Leonardo Vieira Neto; Flávia R van Haute; Lívia L Corrêa; Giovanna A Balarini; Yolanda Shrank; Marcio Goulart; Mônica R Gadelha
Journal:  Growth Horm IGF Res       Date:  2008-03-17       Impact factor: 2.372

9.  Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly.

Authors:  Moisés Mercado; Baldomero González; Carolina Sandoval; Yoshua Esquenazi; Fernando Mier; Guadalupe Vargas; Ana Laura Espinosa de los Monteros; Ernesto Sosa
Journal:  J Clin Endocrinol Metab       Date:  2008-07-08       Impact factor: 5.958

Review 10.  The current status of IGF-I assays--a 2009 update.

Authors:  Jan Frystyk; Pamela Freda; David R Clemmons
Journal:  Growth Horm IGF Res       Date:  2009-10-08       Impact factor: 2.372

View more
  3 in total

Review 1.  Is there a role for early chemotherapy in the management of pituitary adenomas?

Authors:  Andrew L Lin; Melissa W Sum; Lisa M DeAngelis
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

2.  Early postoperative prediction of both disease remission and long-term disease control in acromegaly using the oral glucose tolerance test.

Authors:  Kiyohiko Sakata; Yui Nagata; Nobuyuki Takeshige; Jin Kikuchi; Masato Shikata; Kenji Ashida; Masatoshi Nomura; Motohiro Morioka
Journal:  Hormones (Athens)       Date:  2021-03-18       Impact factor: 2.885

3.  Twenty-four-hour growth hormone profiling in the assessment of acromegaly.

Authors:  Robert D'Arcy; C Hamish Courtney; Una Graham; Steven Hunter; David R McCance; Karen Mullan
Journal:  Endocrinol Diabetes Metab       Date:  2017-12-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.